ArticleJournal of robotic surgery2026
Real-world performance of the SSI Mantra™ robotic system: a multi-centric multi-specialty study evaluating its safety and surgical applications.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robotic-assisted surgery (RAS) in India remains limited by cost and accessibility. The SSI Mantra™ is an indigenous system that was developed to address these barriers. This retrospective cohort study (IDEAL Stage 2b) analyzed 3,694 consecutive RAS cases across 78 centers in India (Feb 2023–Apr 2025) to assess the feasibility, safety, and learning curves of the system. Patient demographics, intraoperative metrics, and outcomes were extracted from prospectively maintained databases. Surgeons were grouped by experience quartiles (Q1–Q4) to analyze console time, conversions, and length of hospital stay (LOS) using descriptive and adjusted regression models. Learning curves were evaluated using continuous cumulative sum (CUSUM) analysis. Mean age was 51 years ± 15.8, with 57.2% being male. Mean blood loss was 75.4 ml ± 52.6; intraoperative adverse events (AEs) occurred in 0.6% of cases. Median LOS was 3 days (IQR: 2–4). Overall conversion rate was 4.1% (95% CI: 3.6–5.0%), varying by the procedure type and surgeon’s experience. More experienced surgeons (Q4) had shorter adjusted console times (154 vs. 169.6 min, p < 0.001) and lower conversion rates. Longer console time was linked to lower conversion odds. LOS increased with conversions but was more stable for experienced surgeons. CUSUM charts showed clear learning curve differences. No device-related AEs were reported. These results suggest that SSI Mantra™ is feasible, with minimal intraoperative AEs for diverse and complex procedures, with consistent performance across centers and specialties. Its lower capital cost may expand RAS access in India. Surgeon experiences improved efficiency and outcomes, supporting structured training. Long-term outcomes and comparative effectiveness warrant further study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.